Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

131.62 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 834
Open 131.62
Bid (Size) 133.00 (100)
Ask (Size) 147.12 (2,700)
Prev. Close 131.62
Today's Range 131.62 - 131.62
52wk Range 40.35 - 134.28
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Grail Could Be the Sleeper Stock Everyone's About to Notice ↗
Grail is on a quest to win in a $50 billion market. 
Via The Motley Fool

Performance

YTD
+29.4%
+29.4%
1 Month
+38.7%
+38.7%
3 Month
+51.0%
+51.0%
6 Month
+28.2%
+28.2%
1 Year
+167.0%
+167.0%

More News

Read More
News headline image
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
Via StockStory
Topics Bankruptcy
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Via StockStory
Guardant Health (NASDAQ:GH) Smashes Q1 Estimates, Raises Full-Year Guidance on Soaring Screening Revenue ↗
Via Chartmill
News headline image
3 Unprofitable Stocks Walking a Fine Line
Via StockStory
Topics Electric Vehicles
News headline image
3 Reasons GH is Risky and 1 Stock to Buy Instead
Via StockStory
Topics Bankruptcy Stocks Supply Chain
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders
Via StockStory
News headline image
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
From Guardant Health, Inc.
Via Business Wire
News headline image
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Growth Stocks We’re Skeptical Of
Via StockStory
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Via StockStory
News headline image
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Guardant Health (GH) Stock Is Down Today
Via StockStory
News headline image
The Top 5 Analyst Questions From Guardant Health’s Q1 Earnings Call
Via StockStory
Topics Earnings
News headline image
Guardant Health (GH) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth
Via StockStory
News headline image
Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars
Via StockStory
News headline image
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Earnings: What To Look For From GH
Via StockStory
News headline image
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
From Guardant Health, Inc.
Via Business Wire

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?
Yes, Guardant Health, Inc. - Common Stock is publicly traded.
What exchange does Guardant Health, Inc. - Common Stock trade on?
Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Guardant Health, Inc. - Common Stock?
The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market
What is the current price of Guardant Health, Inc. - Common Stock?
The current price of Guardant Health, Inc. - Common Stock is 131.62
When was Guardant Health, Inc. - Common Stock last traded?
The last trade of Guardant Health, Inc. - Common Stock was at 06/12/26 04:00 PM ET
What is the market capitalization of Guardant Health, Inc. - Common Stock?
The market capitalization of Guardant Health, Inc. - Common Stock is 13.33B
How many shares of Guardant Health, Inc. - Common Stock are outstanding?
Guardant Health, Inc. - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.